ABSTRACT
Pulmonory embolism takes the third place in cardiovascular mortality structure. Separate clinical symptoms don't have adequate sensibility and specificity for pulmonary embolism verification. For pulmonary embolism diagnosis are usually used clinical probability scales. Clinical markers, pulmonic ventricle dysfunction markers, and myocardial injury markers determine risk stratification. Methods for diagnosis and treatment of pulmonary embolism are based on risk levels. In case of suspected pulmonary embolism the treatment should be prescribed immediately without waiting for diagnosis approval. Pulmonary embolism. accompanied with shock and hypotension is. an absolute thrombolytic therapy indication. According to data, provided by authors, efficacy and safety of prourokinase appeared to be as effective and safe as alteplase according to clinical and instrumental criteria. Alteplase effectiveness is higher than prourokinase in case of short anamnesis (<3 days), while in case of long anamnesis (>3 days) proukinase has the advantage of alteplase., To prevent repeated venous thromboembolism should be prescribed indirect anticoagulant (Vitamin K antaonist) or factor Xa inhibitor oral inticoagulant rivaroxaban.
Subject(s)
Pulmonary Embolism , Anticoagulants/therapeutic use , Humans , Pulmonary Embolism/diagnosis , Pulmonary Embolism/drug therapyABSTRACT
Pulmonay thromboembolism is a common difficult-to-diagnose pathology not infrequently with a lethal outcome. There are many factors leading to hypercoagulation. One of them is intake of hormonal contraceptives to which doctors sometimes do not pay due attention. This paper reports two cases of acute coagulopathy with massive pulmonary thromboembolism in young women using these agents during a long period.
